Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Interest Expenses (2016 - 2025)

Tg Therapeutics (TGTX) has 9 years of Interest Expenses data on record, last reported at $6.5 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 5.74% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $26.7 million, up 11.23%, while the annual FY2025 figure was $26.7 million, 11.23% up from the prior year.
  • Interest Expenses reached $6.5 million in Q4 2025 per TGTX's latest filing, down from $6.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $10.8 million in Q3 2024 and bottomed at $1.0 million in Q3 2021.
  • Average Interest Expenses over 5 years is $4.0 million, with a median of $2.9 million recorded in 2022.
  • The widest YoY moves for Interest Expenses: up 195.32% in 2025, down 37.95% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $1.1 million in 2021, then soared by 165.25% to $2.9 million in 2022, then decreased by 15.06% to $2.4 million in 2023, then skyrocketed by 185.11% to $6.9 million in 2024, then fell by 5.74% to $6.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $6.5 million in Q4 2025, $6.7 million in Q3 2025, and $6.7 million in Q2 2025.